{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:01:30Z","timestamp":1787032890925,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,4]]},"DOI":"10.7759\/cureus.81725","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T18:09:40Z","timestamp":1743790180000},"source":"Crossref","is-referenced-by-count":3,"title":["Pulmonary Coccidioidomycosis in a Ruxolitinib-Treated Polycythemia Vera Patient: A Case Study and Literature Review"],"prefix":"10.7759","author":[{"given":"Angela M","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blessing","family":"Eze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinta","family":"Mbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Walls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Rabany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Rolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S34434","article-title":"Coccidioidomycosis: epidemiology","volume":"5","author":"Brown J","year":"2013","unstructured":"Brown J, Benedict K, Park BJ, Thompson GR 3rd. Coccidioidomycosis: epidemiology. Clin Epidemiol. 2013, 5:185-97. 10.2147\/CLEP.S34434","journal-title":"Clin Epidemiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis1028","article-title":"Coccidioidomycosis acquired in Washington State","volume":"56","author":"Marsden-Haug N","year":"2013","unstructured":"Marsden-Haug N, Goldoft M, Ralston C, et al.. Coccidioidomycosis acquired in Washington State. Clin Infect Dis. 2013, 56:847-50. 10.1093\/cid\/cis1028","journal-title":"Clin Infect Dis"},{"key":"ref3","unstructured":"Reported Cases of Valley Fever. (2024). Accessed. March 19, 2025: https:\/\/www.cdc.gov\/valley-fever\/php\/statistics\/index.html."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myy095","article-title":"Update on the epidemiology of coccidioidomycosis in the United States","volume":"57","author":"McCotter OZ","year":"2019","unstructured":"McCotter OZ, Benedict K, Engelthaler DM, et al.. Update on the epidemiology of coccidioidomycosis in the United States. Med Mycol. 2019, 57:S30-40. 10.1093\/mmy\/myy095","journal-title":"Med Mycol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1406.045","article-title":"Public health surveillance for coccidioidomycosis in Arizona","volume":"1111","author":"Sunenshine RH","year":"2007","unstructured":"Sunenshine RH, Anderson S, Erhart L, Vossbrink A, Kelly PC, Engelthaler D, Komatsu K. Public health surveillance for coccidioidomycosis in Arizona. Ann N Y Acad Sci. 2007, 1111:96-102. 10.1196\/annals.1406.045","journal-title":"Ann N Y Acad Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1128\/iai.32.2.897-907.1981","article-title":"Human sex hormones stimulate the growth and maturation of Coccidioides immitis","volume":"32","author":"Drutz DJ","year":"1981","unstructured":"Drutz DJ, Huppert M, Sun SH, McGuire WL. Human sex hormones stimulate the growth and maturation of Coccidioides immitis. Infect Immun. 1981, 32:897-907. 10.1128\/iai.32.2.897-907.1981","journal-title":"Infect Immun"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1086\/319203","article-title":"Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995-1996","volume":"32","author":"Rosenstein NE","year":"2001","unstructured":"Rosenstein NE, Emery KW, Werner SB, et al.. Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995-1996. Clin Infect Dis. 2001, 32:708-15. 10.1086\/319203","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.1.113","article-title":"Coccidioidomycosis in patients with hematologic malignancies","volume":"165","author":"Blair JE","year":"2005","unstructured":"Blair JE, Smilack JD, Caples SM. Coccidioidomycosis in patients with hematologic malignancies. Arch Intern Med. 2005, 165:113-7. 10.1001\/archinte.165.1.113","journal-title":"Arch Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02230-06","article-title":"Epidemiologic, clinical, and diagnostic aspects of coccidioidomycosis","volume":"45","author":"Saubolle MA","year":"2007","unstructured":"Saubolle MA, McKellar PP, Sussland D. Epidemiologic, clinical, and diagnostic aspects of coccidioidomycosis. J Clin Microbiol. 2007, 45:26-30. 10.1128\/JCM.02230-06","journal-title":"J Clin Microbiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12144","article-title":"The utility of diagnostic testing for active coccidioidomycosis in solid organ transplant recipients","volume":"13","author":"Mendoza N","year":"2013","unstructured":"Mendoza N, Blair JE. The utility of diagnostic testing for active coccidioidomycosis in solid organ transplant recipients. Am J Transplant. 2013, 13:1034-9. 10.1111\/ajt.12144","journal-title":"Am J Transplant"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12372","article-title":"Diagnosis, treatment, and outcomes of coccidioidomycosis in allogeneic stem cell transplantation","volume":"17","author":"Mendoza N","year":"2015","unstructured":"Mendoza N, Noel P, Blair JE. Diagnosis, treatment, and outcomes of coccidioidomycosis in allogeneic stem cell transplantation. Transpl Infect Dis. 2015, 17:380-8. 10.1111\/tid.12372","journal-title":"Transpl Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03328.x","article-title":"Coccidioidomycosis in liver transplant recipients in an endemic area","volume":"11","author":"Vucicevic D","year":"2011","unstructured":"Vucicevic D, Carey EJ, Blair JE. Coccidioidomycosis in liver transplant recipients in an endemic area. Am J Transplant. 2011, 11:111-9. 10.1111\/j.1600-6143.2010.03328.x","journal-title":"Am J Transplant"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myy019","article-title":"Coccidioidomycosis in selected immunosuppressed hosts","volume":"57","author":"Blair JE","year":"2019","unstructured":"Blair JE, Ampel NM, Hoover SE. Coccidioidomycosis in selected immunosuppressed hosts. Med Mycol. 2019, 57:S56-63. 10.1093\/mmy\/myy019","journal-title":"Med Mycol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw360","article-title":"2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the treatment of coccidioidomycosis","volume":"63","author":"Galgiani JN","year":"2016","unstructured":"Galgiani JN, Ampel NM, Blair JE, et al.. 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016, 63:e112-46. 10.1093\/cid\/ciw360","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13373","article-title":"JAK1\/2 inhibition impairs T-cell function in vitro and in patients with myeloproliferative neoplasms","volume":"169","author":"Parampalli Yajnanarayana S","year":"2015","unstructured":"Parampalli Yajnanarayana S, St\u00fcbig T, Cornez I, et al.. JAK1\/2 inhibition impairs T-cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol. 2015, 169:824-33. 10.1111\/bjh.13373","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-019-00350-w","article-title":"Small-molecule protein kinases inhibitors and the risk of fungal infections","volume":"13","author":"Bechman K","year":"2019","unstructured":"Bechman K, Galloway JB, Winthrop KL. Small-molecule protein kinases inhibitors and the risk of fungal infections. Curr Fungal Infect Rep. 2019, 13:229-43. 10.1007\/s12281-019-00350-w","journal-title":"Curr Fungal Infect Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-015-0284-z","article-title":"Immunological consequences of JAK inhibition: friend or foe?","volume":"10","author":"McLornan DP","year":"2015","unstructured":"McLornan DP, Khan AA, Harrison CN. Immunological consequences of JAK inhibition: friend or foe?. Curr Hematol Malig Rep. 2015, 10:370-9. 10.1007\/s11899-015-0284-z","journal-title":"Curr Hematol Malig Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2017.06.015","article-title":"Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis","volume":"22","author":"Hirano A","year":"2017","unstructured":"Hirano A, Yamasaki M, Saito N, et al.. Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis. Respir Med Case Rep. 2017, 22:87-90. 10.1016\/j.rmcr.2017.06.015","journal-title":"Respir Med Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113132","article-title":"Ruxolitinib-associated infections in polycythemia vera: review of the literature, clinical significance, and recommendations","volume":"12","author":"Sadjadian P","year":"2020","unstructured":"Sadjadian P, Wille K, Griesshammer M. Ruxolitinib-associated infections in polycythemia vera: review of the literature, clinical significance, and recommendations. Cancers (Basel). 2020, 12:10.3390\/cancers12113132","journal-title":"Cancers (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek S","year":"2016","unstructured":"Verstovsek S, Vannucchi AM, Griesshammer M, et al.. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016, 101:821-9. 10.3324\/haematol.2016.143644","journal-title":"Haematologica"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3242-8","article-title":"Infections associated with ruxolitinib: study in the French Pharmacovigilance database","volume":"97","author":"Sylvine P","year":"2018","unstructured":"Sylvine P, Thomas S, Pirayeh E. Infections associated with ruxolitinib: study in the French Pharmacovigilance database. Ann Hematol. 2018, 97:913-4. 10.1007\/s00277-018-3242-8","journal-title":"Ann Hematol"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa167","article-title":"Coccidioidomycosis in patients treated with ruxolitinib","volume":"7","author":"Kusne Y","year":"2020","unstructured":"Kusne Y, Kimes KE, Feller FF, et al.. Coccidioidomycosis in patients treated with ruxolitinib. Open Forum Infect Dis. 2020, 7:167.","journal-title":"Open Forum Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03907-1","article-title":"Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects","volume":"84","author":"Aslanis V","year":"2019","unstructured":"Aslanis V, Umehara K, Huth F, et al.. Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects. Cancer Chemother Pharmacol. 2019, 84:749-57. 10.1007\/s00280-019-03907-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011405663","article-title":"The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers","volume":"52","author":"Shi JG","year":"2012","unstructured":"Shi JG, Chen X, Emm T, et al.. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol. 2012, 52:809-18. 10.1177\/0091270011405663","journal-title":"J Clin Pharmacol"},{"key":"ref25","unstructured":"JAKAFI. (2023). Accessed. April 21, 2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202192s015lbl.pdf."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(99)80371-4","article-title":"Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID (National Institute of Allergy and Infectious Disease) Mycoses Study Group","volume":"98","author":"Catanzaro A","year":"1995","unstructured":"Catanzaro A, Galgiani JN, Levine BE, et al.. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID (National Institute of Allergy and Infectious Disease) Mycoses Study Group. Am J Med. 1995, 98:249-56. 10.1016\/s0002-9343(99)80371-4","journal-title":"Am J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi A","year":"2011","unstructured":"Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011, 86:1188-91. 10.4065\/mcp.2011.0518","journal-title":"Mayo Clin Proc"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek S","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, et al.. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010, 363:1117-27. 10.1056\/NEJMoa1002028","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00392-1","article-title":"Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis","volume":"11","author":"Palandri F","year":"2021","unstructured":"Palandri F, Palumbo GA, Elli EM, et al.. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer J. 2021, 11:4. 10.1038\/s41408-020-00392-1","journal-title":"Blood Cancer J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/332520-pulmonary-coccidioidomycosis-in-a-ruxolitinib-treated-polycythemia-vera-patient-a-case-study-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T18:09:53Z","timestamp":1743790193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/332520-pulmonary-coccidioidomycosis-in-a-ruxolitinib-treated-polycythemia-vera-patient-a-case-study-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.81725","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,4]]}}}